Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$8.01 – $18.10
10% from low
Exchange
OTC Link
ADRC
Borrow rate
3.54%
Moderate
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $293.51B | $301.98B | $305.07B | $363.78B | $410.50B | $461.51B | $508.64B | $530.16B |
| Cost of revenue | $131.90B | $142.17B | $150.77B | $173.19B | $194.42B | $219.01B | $236.66B | $259.06B |
| Gross profit | $161.61B | $159.81B | $154.30B | $190.59B | $216.08B | $242.50B | $271.98B | $271.10B |
| Gross margin | 55.1% | 52.9% | 50.6% | 52.4% | 52.6% | 52.5% | 53.5% | 51.1% |
| R&D | $19.58B | $21.76B | $22.52B | $26.78B | $31.06B | $31.40B | $31.45B | $30.92B |
| Operating income | $60.80B | $54.50B | $50.95B | $69.57B | $72.65B | $78.38B | $87.58B | $65.92B |
| EBITDA | $74.19B | $74.42B | $77.22B | $96.38B | $102.09B | $112.87B | $121.77B | $115.16B |
| Net income | $41.22B | $34.88B | $31.90B | $44.09B | $45.78B | $49.64B | $53.67B | $37.59B |
| Net margin | 14.0% | 11.6% | 10.5% | 12.1% | 11.2% | 10.8% | 10.6% | 7.1% |
| EPS (diluted) | 65.76 | 55.64 | 50.82 | 70.16 | 72.91 | 79.24 | 86.05 | 60.72 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $544.9B | $67.15 | $63.40–$70.84 | 1 |
| 2028 | $576.7B | $78.85 | $74.45–$83.18 | 1 |
| 2029 | $610.1B | $92.85 | $87.67–$97.96 | 1 |
| 2030 | $643.4B | $101.46 | $95.79–$107.04 | 1 |
Forward consensus · source: Financial Modeling Prep
SYSMEX CORP UNSP/ASDR
No one on the platform currently holds SSMXY.
No tracked institution reports a position in SSMXY as of their last filing.
| Execution date | Ratio |
|---|---|
| 2024-04-02 | 1.5-for-1 |
| 2014-04-08 | 2-for-1 |
No one on the platform has traded SSMXY yet.
| $7.4B |
| — |
| MSMKFMatsukiyoCocokara & Co. | $14.60 | +0.00% | $5.7B | — |
| SHTDFSinopharm Group Co. Ltd. | $2.13 | +0.00% | $6.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× earnings vs its 0.3× historical median P/E.
Fair value ≈ $21.58 · price $9.01 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.